BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...

"US demand for Mounjaro and Zepbound is strong and growing as access ... although Wegovy's lowest 0.25 mg dose remains in limited supply, according to the FDA. Both Ozempic and Wegovy still ...

But regardless of what patients take them for, there is an outstanding concern: the muscle loss that often accompanies rapid ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

If you’ve been trying to reach a healthier weight, you may be considering semaglutide medications like Ozempic and Wegovy.